InvestorsHub Logo
Followers 0
Posts 484
Boards Moderated 0
Alias Born 10/10/2014

Re: None

Friday, 02/24/2017 1:11:22 PM

Friday, February 24, 2017 1:11:22 PM

Post# of 2099
The extended survival tail is encouraging, and indicates that patients are having durable responses. Durable responses are not commonly seen with most oncology treatments, but have been a hallmark of leading immunotherapies such as Bristol-Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab), and
Merck’s (NYSE: MRK) Keytruda (pembrolizumab).

http://www.baystreet.ca/articles/research_reports/lifesci/VBL022217.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent VBLT News